Quest Diagnostics - DGX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $146.67
  • Forecasted Upside: 6.31%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$137.96
▼ -0.87 (-0.63%)

This chart shows the closing price for DGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quest Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DGX

Analyst Price Target is $146.67
▲ +6.31% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $146.67, with a high forecast of $160.00 and a low forecast of $130.00. The average price target represents a 6.31% upside from the last price of $137.96.

This chart shows the closing price for DGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 contributing investment analysts is to hold stock in Quest Diagnostics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
12/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
3/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
9/16/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
12/15/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
5/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/30/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$152.00 ➝ $155.00Low
4/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$138.00 ➝ $144.00Low
4/24/2024CitigroupBoost TargetNeutral ➝ Neutral$135.00 ➝ $145.00Low
4/24/2024UBS GroupBoost TargetNeutral ➝ Neutral$139.00 ➝ $146.00Low
4/24/2024Truist FinancialBoost TargetHold ➝ Hold$145.00 ➝ $150.00Low
4/24/2024MizuhoBoost TargetBuy ➝ Buy$150.00 ➝ $155.00Low
3/20/2024Truist FinancialReiterated RatingHold ➝ Hold$145.00Low
2/26/2024Leerink PartnrsReiterated RatingMarket PerformLow
2/26/2024SVB LeerinkInitiated CoverageMarket Perform$135.00Low
2/7/2024Jefferies Financial GroupUpgradeHold ➝ Buy$140.00 ➝ $155.00Low
2/2/2024Truist FinancialLower TargetHold ➝ Hold$150.00 ➝ $145.00Low
1/3/2024BarclaysInitiated CoverageEqual Weight$145.00Low
12/20/2023Truist FinancialBoost TargetHold ➝ Hold$145.00 ➝ $150.00Low
12/12/2023Bank of AmericaUpgradeNeutral ➝ Buy$140.00 ➝ $160.00Low
12/11/2023CitigroupBoost TargetNeutral ➝ Neutral$130.00 ➝ $145.00Low
12/7/2023UBS GroupBoost TargetNeutral ➝ Neutral$135.00 ➝ $137.00Low
11/17/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$148.00 ➝ $149.00Low
11/6/2023Piper SandlerBoost TargetNeutral ➝ Neutral$130.00 ➝ $140.00Low
10/25/2023CitigroupLower TargetNeutral ➝ Neutral$142.00 ➝ $130.00Low
10/16/2023Piper SandlerLower TargetNeutral ➝ Neutral$145.00 ➝ $130.00Low
10/11/2023Evercore ISILower Target$136.00 ➝ $130.00Low
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$145.00Low
6/29/2023Piper SandlerInitiated CoverageNeutralLow
5/2/2023Bank of AmericaDowngradeBuy ➝ Neutral$166.00 ➝ $148.00Low
4/3/2023CitigroupUpgradeSell ➝ Neutral$125.00 ➝ $142.00Low
3/17/2023MizuhoReiterated RatingBuy$165.00Low
3/17/2023Truist FinancialLower TargetHold$170.00 ➝ $160.00Low
2/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$135.00 ➝ $140.00Low
1/25/2023Credit Suisse GroupBoost TargetNeutral$143.00 ➝ $146.00Low
1/23/2023Evercore ISIInitiated CoverageInline$159.00Low
1/12/2023Robert W. BairdBoost TargetNeutral$143.00 ➝ $154.00Low
1/6/2023Morgan StanleyBoost TargetEqual Weight$146.00 ➝ $158.00Low
12/14/2022MizuhoBoost TargetBuy$160.00 ➝ $165.00Low
11/17/2022CitigroupDowngradeNeutral ➝ Sell$145.00 ➝ $125.00Low
10/21/2022Morgan StanleyBoost TargetEqual Weight$142.00 ➝ $146.00Low
10/21/2022Deutsche Bank AktiengesellschaftBoost TargetHold$129.00 ➝ $140.00Low
10/20/2022William BlairReiterated RatingOutperformLow
8/22/2022Morgan StanleyReiterated RatingEqual Weight$142.00Low
4/25/2022Wells Fargo & CompanyBoost TargetEqual Weight$145.00 ➝ $150.00Medium
4/24/2022UBS GroupBoost Target$139.00 ➝ $150.00Low
4/22/2022Bank of AmericaLower TargetBuy$166.00 ➝ $163.00High
4/4/2022CitigroupDowngradeBuy ➝ Neutral$175.00 ➝ $140.00Low
2/23/2022UBS GroupDowngradeBuy ➝ Neutral$160.00 ➝ $139.00Medium
2/14/2022Morgan StanleyLower TargetEqual Weight$159.00 ➝ $145.00High
2/4/2022Wells Fargo & CompanyLower TargetEqual Weight$160.00 ➝ $145.00Medium
2/4/2022Robert W. BairdLower Target$162.00 ➝ $146.00Medium
2/2/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$135.00Medium
1/28/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$190.00 ➝ $129.00Medium
1/19/2022Truist FinancialLower Target$170.00 ➝ $160.00Low
1/13/2022Robert W. BairdLower Target$173.00 ➝ $162.00High
1/10/2022Deutsche Bank AktiengesellschaftBoost Target$160.00 ➝ $190.00High
1/5/2022Truist FinancialBoost Target$150.00 ➝ $170.00High
12/17/2021Morgan StanleyLower TargetEqual Weight$165.00 ➝ $159.00Low
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$150.00 ➝ $160.00Medium
12/13/2021KeyCorpBoost TargetOverweight$168.00 ➝ $170.00High
10/26/2021Wells Fargo & CompanyBoost TargetEqual Weight$140.00 ➝ $150.00Low
10/22/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$150.00 ➝ $160.00Low
9/10/2021CitigroupBoost TargetBuy$158.00 ➝ $181.00High
9/1/2021KeyCorpBoost TargetIn-Line ➝ Overweight$144.00 ➝ $168.00Low
8/31/2021Morgan StanleyBoost TargetEqual Weight$136.00 ➝ $165.00High
8/19/2021MizuhoBoost TargetBuy$158.00 ➝ $166.00High
8/13/2021Credit Suisse GroupBoost TargetNeutral$135.00 ➝ $150.00Low
7/23/2021Jefferies Financial GroupInitiated CoverageBuy$160.00Low
5/12/2021MizuhoBoost TargetBuy$149.00 ➝ $158.00Medium
5/4/2021UBS GroupUpgradeNeutral ➝ Buy$135.00 ➝ $158.00High
3/18/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$137.00Low
3/12/2021Morgan StanleyBoost TargetEqual Weight$130.00 ➝ $136.00Low
3/12/2021Robert W. BairdDowngradeOutperform ➝ Neutral$137.00Low
1/29/2021CitigroupBoost Target$151.00 ➝ $158.00Low
12/17/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
10/26/2020MizuhoBoost TargetBuy$144.00 ➝ $149.00Medium
10/23/2020Wells Fargo & CompanyReiterated RatingHoldLow
10/21/2020ArgusUpgradeHold ➝ Buy$135.00Medium
10/14/2020Jefferies Financial GroupBoost TargetBuy$125.00 ➝ $134.00Medium
7/24/2020Deutsche Bank AktiengesellschaftBoost TargetTop Pick ➝ Buy$140.00 ➝ $150.00Medium
7/24/2020MizuhoBoost TargetBuy$114.00 ➝ $144.00Medium
7/24/2020CitigroupBoost TargetBuy$130.00 ➝ $151.00Medium
7/14/2020Credit Suisse GroupBoost TargetNeutral$126.00 ➝ $128.00High
7/14/2020Bank of AmericaUpgradeNeutral ➝ Buy$142.00High
6/9/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$90.00 ➝ $120.00Low
6/1/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$140.00High
5/21/2020SunTrust BanksBoost TargetHold$110.00 ➝ $130.00Low
5/20/2020Morgan StanleyBoost TargetOverweight$139.00 ➝ $146.00Medium
5/5/2020UBS GroupBoost TargetNeutral$106.00 ➝ $111.00Low
4/30/2020Bank of AmericaBoost TargetNeutral$105.00 ➝ $120.00Low
4/28/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$95.00 ➝ $139.00High
4/27/2020Wolfe ResearchUpgradeUnderperform ➝ Market Perform$116.00Medium
4/27/2020CitigroupUpgradeNeutral ➝ Buy$113.00 ➝ $130.00High
4/24/2020Credit Suisse GroupReiterated RatingHold$100.00Low
4/23/2020JPMorgan Chase & Co.Boost TargetNeutral$87.00 ➝ $111.00Medium
4/23/2020SunTrust BanksBoost TargetHold$100.00 ➝ $110.00Low
4/23/2020BarclaysBoost TargetEqual Weight$93.00 ➝ $99.00Low
4/23/2020Wells Fargo & CompanyBoost TargetUnderweight$80.00 ➝ $90.00Low
4/22/2020CfraDowngradeStrong-Buy ➝ Hold$140.00 ➝ $106.00Medium
4/16/2020MizuhoLower TargetBuy$110.00 ➝ $106.00Medium
4/13/2020SunTrust BanksLower TargetHold$115.00 ➝ $100.00Low
4/2/2020JPMorgan Chase & Co.Lower TargetNeutral$99.00 ➝ $87.00Low
3/30/2020Wells Fargo & CompanyLower TargetUnderweight$100.00 ➝ $80.00Low
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00High
3/26/2020BarclaysLower TargetEqual Weight$106.00 ➝ $93.00Low
3/5/2020CfraUpgradeHold ➝ Strong-Buy$116.00 ➝ $140.00Low
2/10/2020MizuhoBoost TargetBuy$116.00 ➝ $122.00Low
2/3/2020CitigroupBoost TargetNeutral$110.00 ➝ $113.00Low
1/31/2020Bank of AmericaBoost TargetNeutral$110.00 ➝ $116.00Low
1/31/2020Robert W. BairdBoost TargetOutperform$113.00 ➝ $118.00Low
1/30/2020Piper SandlerBoost TargetHold$102.00 ➝ $107.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$100.00Low
1/7/2020BarclaysDowngradeOverweight ➝ Equal Weight$106.00Medium
1/3/2020Bank of AmericaDowngradeNeutral ➝ UnderperformLow
12/19/2019Bank of AmericaUpgradeUnderperform ➝ Neutral$94.00 ➝ $110.00Low
10/21/2019UBS GroupLower TargetNeutral$103.00 ➝ $102.00Low
8/23/2019Morgan StanleyBoost TargetOverweight$111.00 ➝ $121.00High
8/8/2019Evercore ISIReiterated RatingBuy$108.00Low
7/24/2019JPMorgan Chase & Co.Boost TargetNeutral$100.00 ➝ $111.00Low
7/24/2019Morgan StanleyBoost TargetOverweight$104.00 ➝ $111.00Low
7/24/2019Credit Suisse GroupBoost TargetNeutral$99.00 ➝ $105.00Low
7/15/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$90.00 ➝ $85.00High
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 15 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 6 very negative mentions
12/16/2023
  • 20 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/15/2024
  • 29 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/14/2024
  • 27 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/15/2024
  • 22 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 35 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 25 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/13/2024

Current Sentiment

  • 25 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Quest Diagnostics logo
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More

Today's Range

Now: $137.96
Low: $137.82
High: $139.13

50 Day Range

MA: $137.00
Low: $125.92
High: $144.34

52 Week Range

Now: $137.96
Low: $119.59
High: $145.62

Volume

81,465 shs

Average Volume

1,002,000 shs

Market Capitalization

$15.33 billion

P/E Ratio

18.57

Dividend Yield

2.00%

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Quest Diagnostics?

The following sell-side analysts have issued research reports on Quest Diagnostics in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Piper Sandler, StockNews.com, SVB Leerink LLC, TheStreet, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for DGX.

What is the current price target for Quest Diagnostics?

12 Wall Street analysts have set twelve-month price targets for Quest Diagnostics in the last year. Their average twelve-month price target is $146.67, suggesting a possible upside of 6.3%. Bank of America Co. has the highest price target set, predicting DGX will reach $160.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $130.00 for Quest Diagnostics in the next year.
View the latest price targets for DGX.

What is the current consensus analyst rating for Quest Diagnostics?

Quest Diagnostics currently has 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DGX, but not buy more shares or sell existing shares.
View the latest ratings for DGX.

What other companies compete with Quest Diagnostics?

Other companies that are similar to Quest Diagnostics include Laboratory Co. of America, DaVita, Chemed, R1 RCM and CorVel. Learn More about companies similar to Quest Diagnostics.

How do I contact Quest Diagnostics' investor relations team?

Quest Diagnostics' physical mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company's listed phone number is (973) 520-2700 and its investor relations email address is [email protected]. The official website for Quest Diagnostics is www.questdiagnostics.com. Learn More about contacing Quest Diagnostics investor relations.